Ivabradina Krka

Ivabradine, the active ingredient in Ivabradina Krka, is a If channel inhibitor presented as an oral tablet for oral use. It treats chronic stable angina and chronic heart failure in adult patients. GNH USA supplies Ivabradina Krka as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradina Krka acts on the cardiac If current to control heart rate in several cardiovascular conditions. - Chronic stable angina: reduces the frequency of angina attacks by lowering heart rate and myocardial oxygen demand. - Chronic heart failure: improves symptoms and lowers the risk of hospitalization by maintaining a slower, more efficient heart rhythm. - Ischemic heart disease: helps manage chest pain through heart‑rate reduction, decreasing cardiac workload.

Adverse reactions may occur with ivabradine therapy.

Common Side Effects: - Visual disturbances (phosphenes): transient luminous phenomena. - Headache: mild to moderate intensity. - Dizziness or light‑headedness. - Fatigue or general weakness.

Serious or Rare Side Effects: - Severe bradycardia: heart rate markedly below normal. - Atrial fibrillation or other arrhythmias. - Symptomatic hypotension: dizziness with low blood pressure.

Ivabradina Krka requires careful clinical monitoring. - Monitor heart rate: obtain baseline and periodic measurements to avoid excessive bradycardia. - Avoid in severe hypotension: contraindicated when systolic blood pressure is markedly low. - Caution with strong CYP3A4 inhibitors: dose adjustment may be necessary. - Use with caution in hepatic impairment: exposure may increase. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Ivabradina Krka can interact with several drug classes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise ivabradine plasma levels. - Co‑administration with other heart‑rate‑lowering agents (beta‑blockers, digoxin): risk of excessive bradycardia. - QT‑prolonging drugs: combined use may increase arrhythmic risk.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): monitor heart rate and adjust dose if needed. - CYP2C9 inhibitors (e.g., fluconazole): may modestly increase exposure. - CYP3A4 inducers (e.g., rifampicin): may reduce therapeutic effect.